Best Cardiac and Vascular Disorders Companies in San Francisco, United States
The 45 best Cardiac and Vascular Disorders companies in San Francisco, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Portola Pharma.
Ranked: Best Cardiac and Vascular Disorders companies in San Francisco
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Portola Pharma Developer of therapeutics for cardiovascular and autoimmune diseases | $296M | 86 mo ago | 369 | — | — | — | — |
| 2 | Tenaya Therapeutics Developer of regenerative and gene therapeutics for heart failure | $248M | 18 mo ago | 141 141 → 93 (-34%) | Benoit Bruneau Co-Founder | WordPressDrupalMySQL+24 | 207 patents Engineered AAV gene‑therapy vectors and CRISPR guides for cardiac PLN mutation treatment | — |
| 3 | Element Science Wearable therapeutic device for treating sudden cardiac arrest | $193M | 77 mo ago | 74 | Uday Kumar Founder | — | — | — |
| 4 | Structure Developer of oral small molecule drugs for chronic diseases | $191M | 48 mo ago | 93 93 → 232 (+149%) | — | MoodleDrupalApple iCloud Mail+32 | — | — |
| 5 | Braveheart Developer of a treatment for hypertrophic cardiomyopathy and related conditions | $185M | 9 mo ago | — | Travis Murdoch CEO & President | — | — | — |
| 6 | Ancora Heart Medical device company pioneering minimally invasive heart failure treatment solutions | $151M | 61 mo ago | 89 89 → 76 (-15%) | Jeff Closs President and CEO | WordPressSentryApple iCloud Mail+24 | 146 patents Patents concentrated in health & consumer products | — |
| 7 | iRhythm Tech Provider of cloud-based cardiac rhythm monitoring devices | $109M | 147 mo ago | 1,657 1,657 → 1,872 (+13%) | — | Adobe Experience ManagerApple iCloud MailJava+24 | — | — |
| 8 | MyoKardia Developing drugs for treating genetic heart diseases | $98M | 118 mo ago | 224 | — | — | 356 patents Small-molecule cardiac myosin inhibitors for hypertrophic cardiomyopathy treatment. | — |
| 9 | Symic Biomedical Developer of compounds to protect against tissue degradation and promote healing during illness or injury | $84M | 87 mo ago | 2 | — | — | 18 patents Synthetic ECM-binding peptidoglycan biomaterials for wound and tissue repair | — |
| 10 | Marea Therapeutics Provider of therapeutics for cardiometabolic diseases | $65M | 26 mo ago | — | Stephen Rahilly Co-Founder | — | — | — |
| 11 | Ionetix Radiopharmaceutical solutions provider specializing in cyclotron technology and targeted alpha therapy | $61M | 5 mo ago | 50 | Kevin Cameron CEO | WordPressMySQLPHP+24 | 9 patents Compact superconducting cyclotron technology for small-scale particle acceleration | 3 job openings |
| 12 | Diadexus Innovating clinical diagnostics with advanced enzyme and immunoassay technologies | $49M | 194 mo ago | 63 | — | — | 166 patents Cardiovascular antibody therapeutics and biomarker assay kits for heart disease diagnostics | — |
| 13 | Spire Health Developer of continuous health monitoring wearable device | $48M | 61 mo ago | 40 | — | — | — | — |
| 14 | TenSixteen Developer of therapeutics to treat multiple diseases | $40M | 54 mo ago | 22 | — | — | — | — |
| 15 | Qardio Manufacturer of digital health devices for remote patient monitoring systems | $27M | 76 mo ago | 17 | — | Cart FunctionalityShopifySentry+46 | 35 patents Home/wearable blood pressure monitoring with integrated biometric data capture and secure device communication | — |
| 16 | Silver Creek Pharma Biopharmaceutical company delivering life-changing medicines through targeted growth factor therapies | $27M | 102 mo ago | 8 | — | — | — | — |
| 17 | VIA Pharmaceuticals Develops compounds for the treatment of cardiovascular and metabolic disease. | $25M | 189 mo ago | 6 | — | — | — | — |
| 18 | SOLEY Therapeutics Developer of stem cell secreted factors for the treatment of myocardial infarction and stroke | $20M | 7 mo ago | 10 | Yerem Yeghiazarians Co-Founder & CEO | — | — | — |
| 19 | Aulisa Developer of wearable wireless vital signs monitoring medical devices | $13M | 55 mo ago | 7 | — | Cart FunctionalityShopifySentry+22 | — | 4 launchs |
| 20 | Moray Medical Provider of smart devices for catheter control | $6M | 66 mo ago | 4 | Phillip Laby Co-Founder and COO | WordPress Block EditorWordPressMySQL+15 | — | — |
| 21 | Biotricity Developer of medical remote monitoring solutions that help prevent and manage chronic diseases | $5M | 28 mo ago | 55 | Waqaas Al-Siddiq Co-Founder & CEO | WordPressMySQLPHP+36 | 2 patents Wearable cardiac monitoring devices integrating touch-sensitive electrode displays | — |
| 22 | Sympara Medical Developer of medical device for hypertension treatment | $4M | 160 mo ago | 3 | — | — | — | — |
| 23 | ReThink Medical Developer wearables for heart failure patients | $3M | 115 mo ago | 4 | — | — | — | — |
| 24 | RCE Provider of smart device to monitor cardiac health | $3M | 33 mo ago | 12 | Atandra Burman Founder & CEO | — | — | — |
| 25 | EndoVention Develops catheters for the removal of blood clots | $2M | 230 mo ago | — | Peter Yorke Co-Founder & CEO | — | 9 patents Inflatable catheter/balloon systems and intravascular venous clot disruption technologies. | — |
| 26 | Theregen Cell-based therapies for cardiovascular indications | $2M | 246 mo ago | — | Michael Siani-Rose Co-Founder & President | — | 36 patents 3D tissue-engineered regenerative therapies for cardiac and ischemic disease treatment | — |
| 27 | Respirix Provider of a monitoring system for congestive heart failure | $1M | 84 mo ago | — | Daniel Burnett Co-Founder | — | 15 patents Respiratory monitoring and pneumonia detection using physiological sensor devices. | — |
| 28 | Thalman Health Manufacturer of body temperature measuring devices | $550K | 134 mo ago | — | James Foody Founder & CEO | — | — | — |
| 29 | Blumio Developer of a contactless health sensor to measure blood pressure and pulse | $448K | 95 mo ago | 8 | — | — | 6 patents Wearable biometric and cardiovascular health monitoring sensors and measurement systems. | — |
| 30 | V-Sense Medical Developer of non-contact vital sign scanner | $250K | 130 mo ago | — | Jeff Nosanov CEO & Founder | — | — | — |
| 31 | iFirst MedTech Innovative point-of-care coagulation diagnostics using iPhone technology for healthcare | $150K | 77 mo ago | 4 | — | — | — | — |
Top 12 Cardiac and Vascular Disorders companies in San Francisco
#1
Series C · San Francisco, California · founded 2009 · 50 employees$61.1Mraised▾
Radiopharmaceutical solutions provider specializing in cyclotron technology and targeted alpha therapy. The company provides full-service radioisotope production and end-to-end radiopharmaceutical manufacturing solutions. It developed a compact superconducting cyclotron used to produce N-13 Ammonia, a PET imaging agent. The company establishes a network of cyclotrons installed near PET programs, making this tracer accessible and affordable. It supports the development and commercialization of targeted alpha therapy (TAT), an emerging cancer therapy utilizing alpha radionuclides. The company is committed to the design, manufacturing, and support of safe and effective radiopharmaceutical products. It offers a turnkey solution eliminating the expense of launching a Cardiac PET program. The company fosters scientific partnerships and sponsorships to deliver advanced radiopharmaceuticals, providing access to scarce diagnostics and therapeutic radiopharmaceuticals.
- Feb 2026Post IPO$30M
- Aug 2024Series C—
- May 2020Series C$37.3M
- Mar 2018Series B$23.8M
#2
Series A · San Francisco, California · founded 2025$185Mraised▾
Developer of a treatment for hypertrophic cardiomyopathy and related conditions. It focuses on addressing the underlying mechanisms of the condition to improve heart performance. The company is advancing its investigational treatment through late-stage clinical development. Hypertrophic cardiomyopathy causes the heart muscle to become abnormally thick, particularly in the left ventricle.
- Nov 2025Series A$185M
#3
Series C · San Francisco, California · founded 2018 · 10 employees$20Mraised▾
Soley Therapeutics is developing stem cell-secreted factors for the treatment of ischemia-related diseases including myocardial infarction and stroke. These drugs will be administered to patients at the time of heart attack and stroke to minimize the damage in the heart and brain respectively. The company's lead product increases cardiomyocyte (heart muscle) viability, decreases infarct scar size, and improves cardiac function in the acute setting of a heart attack.
- Jan 2026Series C$200M
- Dec 2020Series B$20M
#4
Public · San Francisco, California · founded 2016 · 141 employees$248Mraised▾
Developer of regenerative and gene therapeutics for heart failure. The company's pipeline include MYBPC3 for genetic hypertrophic cardiomyopathy, PKP2 for genetic arrhythmogenic right ventricular cardiomyopathy, DWORF for dilated cardiomyopathy, and HDAV6i for heart failure with preserved ejection fraction.
- Feb 2025Grant (prize money)$8M
- Mar 2021Series C$106M
- Oct 2019Series B$92M
- Dec 2016Series A$50M
#5
Series C · San Francisco, California · founded 2022$65.4Mraised▾
Provider of therapeutics for cardiometabolic diseases. It lead program MAR001which is a monoclonal antibody that targets ANGPTL4 to lower remnant cholesterol and improve adipose tissue function.
- Jun 2024Series C$65.4M
#6
Public · San Francisco, California · founded 2017 · 93 employees$191Mraised▾
Developer of oral small molecule drugs for chronic diseases. It offers GPCR structure-based biologic and peptide drugs for pulmonary hypertension, pulmonary fibrosis, type 2 diabetes, and obesity. It has a structure-based technology platform that combines receptor-binding interactions with the simulation of molecular motion and signal transduction for drug development.
- Aug 2022Series B$33M
- Oct 2021Series B$100M
#7
Acquired · San Francisco, California · founded 2003 · 369 employees$296.1Mraised▾
Developer of therapeutics for cardiovascular and autoimmune diseases. The company's products include PRT054021, an oral factor Xa inhibitor for the prevention and treatment of deep vein thrombosis and pulmonary embolism. Also, include PRT060128, an oral and intravenous ADP receptor antagonist for the treatment of patients with the acute coronary syndrome; for the prevention of cardiovascular events in patients undergoing percutaneous coronary intervention; and for secondary prevention of myocardial infarction and stroke. In addition, the company's products include PRT062607, an oral Syk-specific kinase inhibitor for treating chronic inflammatory diseases, and Rheumatoid Arthritis (RA) which is used to treat certain cancers including non-Hodgkin’s lymphoma and chronic lymphocytic leukemia
- Jun 2019Post IPO$53.6M
- Mar 2019Conventional Debt$125M
- Feb 2017Post IPO$150M
- Dec 2016Post IPO$43.2M
#8
Series D · San Francisco, California · founded 2001 · 89 employees$151.3Mraised▾
Medical device company pioneering minimally invasive heart failure treatment solutions. Dedicated to improving the lives of individuals suffering from heart failure, they focus on developing innovative therapies. Their primary offering, a transcatheter device, aims to restore the structure and function of the heart's left ventricle, providing relief to patients who haven't found sufficient help from standard treatments. They conduct clinical studies to evaluate the safety and efficacy of their system, striving to establish it as a valuable option between medication and more invasive procedures. They are committed to advancing heart failure care through research, development, and a dedication to patient well-being. This is a B2B medical device company.
- Jul 2021Series D$80M
- Dec 2018Series C$23.5M
- May 2018Series B$17.8M
- Apr 2010Series B$30M
#9
Series C · San Francisco, California · founded 2013 · 74 employees$192.6Mraised▾
Wearable therapeutic device for treating sudden cardiac arrest. It offers Jewel a wearable patch defibrillator that offers a protection and peace of mind for those at risk of sudden cardiac arrest.
- Mar 2020Series C$145.6M
- Jun 2019Series B$9.5M
- Aug 2016Series B$25M
- Mar 2014Series A$12.5M
#10
Public · San Francisco, California · founded 2014 · 55 employees$4.9Mraised▾
Developer of medical remote monitoring solutions that help prevent and manage chronic diseases. It offers Mobile Cardiac Telemetry wearable medical cardiac monitoring solution. The flagship product bioflux consists of an ECG monitoring device, software†and access to a monitoring lab to diagnose Cardiovascular Disease (CVD) or Coronary Heart Disease (CHD), is an ambulatory monitor that detects arrhythmias, performs remote MCT diagnostic monitoring.
- Mar 2024Post IPO$1M
- Sep 2022Grant (prize money)$238.7K
- Aug 2020Post IPO$1.3M
- Mar 2017Post IPO$1.2M
#11
Series B · San Francisco, California · founded 2012 · 2 employees$84Mraised▾
Developer of compounds to protect against tissue degradation and promote healing during illness or injury. The pipeline candidates include SB-061 for osteoarthritis, and SB-0303 for peripheral vascular disease/vein graft failure, fibrosis, and cancer.
- Apr 2019Series B$11M
- May 2017Series B$30M
- Dec 2015Series A$25.3M
- Sep 2015Grant (prize money)$176.5K
#12
Public · San Francisco, California · founded 2006 · 1657 employees$109.2Mraised▾
Provider of cloud-based cardiac rhythm monitoring devices. It provides Zio ambulatory ECG monitor a wearable patch designed to gather beat-to-beat heart data for the diagnosis of cardiac arrhythmias. The device stores data in the patch and is emailed to the iRhythm cloud at the end of the monitoring period. myZio iPhone app is an add-on for the Zio Patch for physicians to make a diagnosis.
- May 2014Series E$17M
- Apr 2013Series D$16M
- Nov 2012Series C$1.5M
- Nov 2012Series C$3.5M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Cardiac and Vascular Disorders coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.